BioCorRx Announces First Subject Dosed in Phase I Clinical Trial of BICX104, an Implantable…
ANAHEIM, CA, June 30, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that the…